---
title: "NHS National Generic Pharmaceuticals Wave 15b"
ocid: "ocds-h6vhtk-04e2d4"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-04e2d4"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-04e2d4.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-04e2d4.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "NHS ENGLAND"
published: "2025-08-04"
---

# NHS National Generic Pharmaceuticals Wave 15b

Buyer: NHS ENGLAND  
Current stage: Award  
OCID: ocds-h6vhtk-04e2d4

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-04e2d4)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-04e2d4.json)

## Summary

The public procurement process summarised here concerns NHS England's initiative titled "NHS National Generic Pharmaceuticals Wave 15b". It falls within the pharmaceutical products industry (CPV: 33600000) and involves the procurement of goods. The procurement stage is at the completion of the tender, with relevant activities noted as award and contract, asserting its status as complete. NHS England, centrally located in Leeds, is the buying organisation coordinating this open procurement process under the CELEX legal basis. This framework agreement encompasses several regions across the UK, including Midlands, Southwest, London South, Northeast, and others, with the main framework periods starting from 1st October 2025. The tendering process involved open procedure methods, with significant framework and call-off periods allowing potential extensions up to 48 months.

This procurement opportunity offers broad prospects for both SMEs and larger enterprises within the pharmaceutical sector. By engaging with NHS England's extensive framework agreement, businesses can potentially secure stable, long-term contracts that foster growth and expansion within the healthcare supply chain. The framework allows suppliers, including small and medium-sized enterprises, to benefit from large-scale NHS contracts, as evidenced by numerous supplier awards to both SMEs and larger organisations. Businesses offering oral, non-parenteral, and hospital-only pharmaceutical products should find themselves well-suited to participate and thrive within this framework, contingent on eligibility and fulfilment of procurement requirements.

## Notice

NHS National Pharmaceuticals Generic Products - Wave 15b
Offer reference number: CM/PHG/23/5698
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
CM/PHG/23/5698/01 - Orals (plus non-parenteral) Products
CESW: (Midlands and Southwest): 1st October 2025 to 31st May 2027 (20 months)
NWLN: (Northwest and London North): 1st October 2025 to 31st May 2027 (20 months)
LSNE: (London South and Northeast): 1st October 2025 to 31st May 2027 (20 months)

CM/PHG/23/5698/02 - Hospital Only Products
DCE (Midlands) & DSW (Southwest): 1st October 2025 to 30th September 2027 (24 months)

CM/PHG/23/5698/03 - Hospital Only (Housekeeping) Products
DLS (London South) & DNE (Northeast): 1st October 2025 to 31st May 2026 (8 months)
DNW (Northwest) & DLN (London North): 1st October 2025 to 31st January 2027 (16 months)
DCE (Midlands) & DSW (Southwest): 1st October 2025 to 31st May 2026 (8 months)

### Lot Information

Lot 1 - CM/PHG/23/5698/01 - Orals (plus non-parenteral) Products all regions

Lot 1 CM/PHG/23/5698/01 - Orals (plus non-parenteral) Products
CESW: (Midlands and Southwest): 1st October 2025 to 31st May 2027 (20 months)
NWLN: (Northwest and London North): 1st October 2025 to 31st May 2027 (20 months)
LSNE: (London South and Northeast): 1st October 2025 to 31st May 2027 (20 months) Additional information: Price is not the only award criterion and all criteria are stated in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months

Lot 2 - CM/PHG/23/5698/02 - Hospital Only products (DCE & DSW regions)

Lot 2: CM/PHG/23/5698/02 - Hospital Only Products
DCE (Midlands) & DSW (Southwest): 1st October 2025 to 30th September 2027 (24 months) Additional information: Price is not the only award criterion and all criteria are stated in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months

Lot 3 - CM/PHG/23/5698/03 - Hospital Only (Housekeeping) Products

Lot 3: CM/PHG/23/5698/03 - Hospital Only (Housekeeping) Products
DLS (London South) & DNE (Northeast): 1st October 2025 to 31st May 2026 (8 months)
DNW (Northwest) & DLN (London North): 1st October 2025 to 31st January 2027 (16 months)
DCE (Midlands) & DSW (Southwest): 1st October 2025 to 31st May 2026 (8 months) Additional information: Price is not the only award criterion and all criteria are stated in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/045712-2025 |
| Notice type | Tender Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 4 Aug 2025 |
| Submission deadline | 24 Mar 2025 |
| Future notice date | Not specified |
| Award date | 15 Jun 2025 |
| Contract period | 30 Sep 2025 - 31 Jan 2027 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £742,316,345 |
| Lots value | £742,316,345 |
| Awards value | Not specified |
| Contracts value | £1 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS ENGLAND |
| Locality | LEEDS |
| Post town | Leeds |
| Postcode | LS1 4AP |
| Country | England |
| ITL 1 | TLE Yorkshire and The Humber |
| ITL 2 | TLE4 West Yorkshire |
| ITL 3 | TLE42 Leeds |
| Local authority | Leeds |
| Electoral ward | Hunslet & Riverside |
| Westminster constituency | Leeds South |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 103 |
| Supplier names | ACCORD-UK; AGB PHARMA; AGUETTANT; ALISSA HEALTHCARE RESEARCH; AMAROX; AOP ORPHAN; ARCADIA PHARMA LTD T/A ARCADIA MEDICAL; ASCEND LABORATORIES; ASPEN PHARMACARE; ASPIRE PHARMA; AVENTIS PHARMA LTD T/A SANOFI; B. BRAUN MEDICAL; BAXTER HEALTHCARE; BEAUMONT PHARMA; BIOCON; BOWMED IBISQUS; BROWN AND BURK; CELIX PHARMA; CHIESI; CIPLA; COLONIS PHARMA; CONSILIENT HEALTH; CRESCENT PHARMA; CST PHARMA; DAY LEWIS MEDICAL; DESITIN PHARMA; DR.REDDY'S LABORATORIES (UK; DRUGSRUS; ENNOGEN HEALTHCARE; ERAMOL (UK; ESSENTIAL PHARMA; ESTEVE PHARMACEUTICALS; FARMAK PHARMACEUTICALS; FERRING PHARMACEUTICALS; FLEXIPHARM AUSTRADING; FLYNN PHARMA; FOCUS PHARMACEUTICALS; FONTUS HEALTH; FRESENIUS KABI; G.L. PHARMA; GALEN; GALVANY PHARMA; GENNISIUM PHARMA; GLAXOSMITHKLINE; GLENMARK PHARMACEUTICALS EUROPE; HAMELN PHARMA; HIKMA PHARMACEUTICALS; IMMEDICA PHARMA; JCSH PHARMA; KENT PHARMA; LIPOMED; LOGIXX PHARMA; LUCANE PHARMA; LUNDBECK; MACLEODS PHARMA; MACURE PHARMA; MANX HEALTHCARE; MARTINDALE PHARMA; MEDAC PHARMA; MEDREICH; MERCK SHARPE AND DOHME (UK; MERCURY PHARMACEUTICALS; MILPHARM LTD/AUROBINBDO PRIMARY; MORNINGSIDE PHARMAEUTICALS; MSN LABORATORIES EUROPE; MYLAN; NECESSITY SUPPLIES; NEON HEALTHCARE; NEURAXPHARM; NOVUMGEN; OTSUKA PHARMACEUTICALS; PANPHARMA; PARI MEDICAL; PERENNIAL PHARMA; PFIZER; PHOENIX LAB; PIERRE FABRE; PIRAMAL CRITICAL CARE; RECORDATI PHARMACEUTICALS; REIG JOFRE; ROCHE PRODUCTS; ROMA PHARMACEUTICALS; RPH PHARMACEUTICALS; SANDOZ; SCOPE OPHTHALMICS; SEACROSS PHARMACEUTICALS; SELECTIVE SUPPLIES; SOBI (SWEDISH ORPHAN BIOVITRUM; STIRLING ANGLIAN PHARMACEUTICALS; STRIDES PHARMA; SUN PHARMA; SVP PHARMA; SYNCHRONY; TEVA; THEA PHARMACEUTICALS; THORNTON AND ROSS; TILLOMED LABORATORIES; TORBAY PHARMACEUTICALS; TORRENT PHARMA; VANTAGE PHARMACEUTICALS; WAYMADE; WOCKHARDT; ZENTIVA PHARMA |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 4 Aug 2025 at 14:23 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/045712-2025
- 17 Feb 2025 at 15:11 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/005420-2025

## Notice URLs

- http://health.atamis.co.uk
- https://health-family.force.com/s/Welcome
- https://supplierregistration.cabinetoffice.gov.uk
- https://www.england.nhs.uk//
- https://www.judiciary.uk/courts-and-tribunals/high-court/

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-04e2d4. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-04e2d4.json.